Eloxx Pharmaceuticals (NASDAQ: ELOX) has announced that the first two patients have been dosed in its Phase 2b EXACT Study evaluating exaluren in patients with nonsense mutation Alport syndrome (NMAS).
According to Eloxx, topline data from the initial 16-week placebo-controlled portion of the study is expected mid-2027 and a final readout at 32 weeks is expected by the end of 2027.
In a statement, Daniel Gale, professor of nephrology at University College London and consultant nephrologist at the Royal Free London NHS Foundation Trust, commented, “Dosing the first patients in the EXACT Study is a significant step for people living with nonsense mutation Alport syndrome, a disease with a clear genetic cause but no approved treatment that addresses it directly. Patients with this form of Alport syndrome can progress to kidney failure while still in their twenties, so there is real urgency behind bringing genetically targeted therapies like exaluren into clinical testing. Advancing this trial is an important step forward for a patient population that has been underserved for too long.”
